Serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) appears to be an important diagnostic tool for a whole range of diseases. Sensitivities and specificities obtained with this new technology often seem superior to those obtained with current biomarkers. However, reproducibility and standardization are still problematic. The present review gives an overview of the diagnostic value of protein profiles obtained with SELDI in studies on prostate and ovarian cancer. To identify aspects important for protein profiling, we compare and discuss differences in pre- and post-analytical conditions presented in the literature supplemented with some of our own data. Further progress in protein profiling as a diagnostic tool requires a more comprehensive description of technical details in all future studies.
We studied a possible effect of the extent of the acute
phase response after acute myocardial infarction on
the cumulative release of troponin T. The height of the
acute phase response might influence the cumulative
release of troponin T, bound to the myofibrillar structures
of the heart, in a different way compared to the
free cytoplasmic cardiac marker hydroxybutyrate dehydrogenase
(EC 126.96.36.199). To investigate this, the cumulative
amount of C-reactive protein in plasma, i.e.
the quantified acute phase response, was related to
the cumulative plasma release of hydroxybutyrate dehydrogenase
(an established method for infarct sizing)
on the one hand and to that of troponin T on the other
The study was performed in patients receiving
(n=16) and in patients not receiving (n=6) thrombolytic
therapy. Cumulative protein release was calculated using
a two-compartment model for circulating proteins.
Conclusions: The cumulative amount of plasma C-reactive
protein is significantly higher in the patients
not receiving thrombolytic therapy, as is in accordance
with earlier studies. The cumulative amount of troponin
T released is significantly related to the cumulated
concentration of C-reactive protein, especially in
patients not receiving thrombolytic therapy. The intensity
of the acute phase response, estimated from cumulative
plasma C-reactive protein response, has no
effect on the relative proportions of troponin T and hydroxybutyrate
dehydrogenase released into plasma.